124043-72-7

Upstream product

• 271-89-6 1-benzofurane 
• 17070-58-5 benzofuran-2-sulfonyl chloride 
• 7664-41-7 ammonia 

Downstream Products

• 145951-08-2 N-[[(4-bromophenyl)amino]carbonyl]-2-benzofuransulfonamide 

Relevant academic research and scientific papers

Primary Sulfonamide Synthesis Using the Sulfinylamine Reagent N-Sulfinyl- O-(tert-butyl)hydroxylamine, t-BuONSO

Sulfonamides have played a defining role in the history of drug development and continue to be prevalent today. In particular, primary sulfonamides are common in marketed drugs. Here we describe the direct synthesis of these valuable compounds from organometallic reagents and a novel sulfinylamine reagent, t-BuONSO. A variety of (hetero)aryl and alkyl Grignard and organolithium reagents perform well in the reaction, providing primary sulfonamides in good to excellent yields in a convenient one-step process.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3

Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives

The anti-proliferative activity of acylated heterocyclic sulfonamides is described in Vascular Endothelial Growth Factor-dependent Human Umbilical Vascular Endothelial Cells (VEGF-HUVEC) and in HCT116 tumor cells in a soft agar diffusion assay.

ANTITUMOR BENZOYLSULFONAMIDES

The present invention provides antitumor compounds of the formula (I); and antitumor methods.

Diarylsulfonylureas for use in treating secretory diarrhea

This invention provides methods of treating secretory diarrhea or cystic fibrosis in a mammal which comprises administering to a mammal in need thereof an effective amount of diarylsulfonylurea. This invention also describes specific diarylsulfonylureas f

Synthesis and cytotoxic evaluation of substituted sulfonyl-n- hydroxyguanidine derivatives as potential antitumor agents

A series of sulfonyl-N-hydroxygnanidine derivatives was designed and synthesized for cytotoxic evaluation as potential anticancer agents on the basis of the lead compound LY-181984. Replacement of the ureido moiety of the lead compound with hydrexyguanidine provided a stable cytotoxic agent. The conformation of sulfonyl-N-hydroxyguanidine derivatives, such as N-(4- chlorophenyl-)-N-[(benzo[2,3]thiadiazol-4-yl)sulfonyl]-N-hydroxyguanidine (4g), investigated utilizing HMBC NMR, theoretical calculations, and X-ray crystallography, indicated stacking of the two aromatic rings. The derivatives were evaluated for in vitro cytoxicity against five human tumor cell lines, including HepG2, TSGH 8302, COLO 205, KB, and MOLT-4. The cytotoxic activities of the derived compounds against the human tumor cell lines were equal to or greater than that of the lead compound. N-(4- Chlorophenyl)-N'-[[3,5-dichloro-4-(4-nitrophenoxy)phenyl]sulfonyl].N- hydroxyguanidine (4n) and N-(4-chlorophenyl)-N'-[[3,5-dichloro4-(2-chloro-4- nitrophenoxy)phenyl]sulfonyl]-N-hydroxyguanidine (40) exhibited the greatest growth inhibition of solid tumor cell lines. Compound 40 was found to possess antitumor activity against murine K1735/M2 melanoma xenografts.

Antitumor compositions and methods of treatment

This invention provides the use of certain tetra-substituted imidazolidin-2-one derivatives in the treatment of susceptible neoplasms in mammals. Also provided are certain novel tetra-substituted imidazolidin-2-one derivatives and pharmaceutical formulati

Antitumor compositions and methods of treatment

This invention provides the use of certain benzofuransulfonamide, benzothiophenesulfonamide, and indolesulfonamide derivatives in the treatment of susceptible neoplasms in mammals. Also provided are certain novel benzofuransulfonamide and benzothiophenesulfonamide derivatives and their pharmaceutical formulations.